MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab

This study will evaluate the efficacy and safety of finite-duration acalabrutinib plus venetoclax therapy in patients with relapsed CLL or SLL, who have previously responded to first line (1L) cBTKi + BCL2i therapy (± obinutuzumab) and maintained a response for at least two years post-treatment.

Trial Details

NCT ID
NCT07024706
Phase
PHASE2
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Acalabrutinib
  • Venetoclax
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Charlotte, North Carolina, United States|35.22709,-80.84313
  • Charlotte, North Carolina, United States|35.22709,-80.84313
  • Durham, North Carolina, United States|35.99403,-78.89862
  • Winston-Salem, North Carolina, United States|36.09986,-80.24422

Key Eligibility Criteria

  • Participant must be ≥ 18 years at the time of signing informed consent.
  • Diagnosis of relapsed CLL/SLL according to iwCLL guidelines 2018 (Hallek et al. 2018) in need of treatment.
  • Participants must have received only one prior first line treatment with fixed duration covalent BTKi plus BCL2i therapy (± obinutuzumab) with a re…
  • The following data must be available or at least the appropriate samples drawn/acquired prior to dosing:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →